Pieris Pharmaceuticals, Inc. (PIRS): Price and Financial Metrics


Pieris Pharmaceuticals, Inc. (PIRS): $1.60

0.01 (+0.63%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PIRS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PIRS POWR Grades

  • Sentiment is the dimension where PIRS ranks best; there it ranks ahead of 75.26% of US stocks.
  • The strongest trend for PIRS is in Sentiment, which has been heading up over the past 177 days.
  • PIRS's current lowest rank is in the Stability metric (where it is better than 30.15% of US stocks).

PIRS Stock Summary

  • Of note is the ratio of PIERIS PHARMACEUTICALS INC's sales and general administrative expense to its total operating expenses; merely 9.79% of US stocks have a lower such ratio.
  • With a year-over-year growth in debt of -21.14%, PIERIS PHARMACEUTICALS INC's debt growth rate surpasses just 14.46% of about US stocks.
  • The volatility of PIERIS PHARMACEUTICALS INC's share price is greater than that of 85.39% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to PIERIS PHARMACEUTICALS INC, a group of peers worth examining would be MGNX, VTGN, CLLS, TMDI, and MEIP.
  • PIRS's SEC filings can be seen here. And to visit PIERIS PHARMACEUTICALS INC's official web site, go to www.pieris.com.

PIRS Valuation Summary

  • PIRS's price/sales ratio is 3.7; this is 27.45% lower than that of the median Healthcare stock.
  • Over the past 98 months, PIRS's price/earnings ratio has gone up 4.8.

Below are key valuation metrics over time for PIRS.

Stock Date P/S P/B P/E EV/EBIT
PIRS 2023-01-20 3.7 2.9 -3.0 -1.9
PIRS 2023-01-19 3.7 2.9 -3.0 -1.9
PIRS 2023-01-18 3.5 2.8 -2.9 -1.8
PIRS 2023-01-17 3.3 2.6 -2.7 -1.6
PIRS 2023-01-13 3.9 3.1 -3.2 -2.1
PIRS 2023-01-12 3.7 3.0 -3.1 -2.0

PIRS Growth Metrics

    The 4 year cash and equivalents growth rate now stands at -14.14%.
  • The 3 year net income to common stockholders growth rate now stands at -64.4%.
  • Its 4 year price growth rate is now at -16.75%.
PIRS's revenue has moved down $17,780,000 over the prior 33 months.

The table below shows PIRS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 28.499 -57.943 -34.707
2022-06-30 27.186 -63.649 -41.507
2022-03-31 26.773 -18.165 -46.667
2021-12-31 31.418 -7.66 -45.738
2021-09-30 24.852 -10.133 -50.606
2021-06-30 23.734 -3.219 -48.353

PIRS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PIRS has a Quality Grade of C, ranking ahead of 27.39% of graded US stocks.
  • PIRS's asset turnover comes in at 0.193 -- ranking 490th of 561 Business Services stocks.
  • NXTD, ATVI, and AEYE are the stocks whose asset turnover ratios are most correlated with PIRS.

The table below shows PIRS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.193 1 -1.697
2021-03-31 0.279 1 -0.852
2020-12-31 0.254 1 -0.693
2020-09-30 0.359 1 -0.373
2020-06-30 0.456 1 -0.199
2020-03-31 0.398 1 -0.367

PIRS Price Target

For more insight on analysts targets of PIRS, see our PIRS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.50 Average Broker Recommendation 1.25 (Strong Buy)

PIRS Stock Price Chart Interactive Chart >

Price chart for PIRS

PIRS Price/Volume Stats

Current price $1.60 52-week high $3.68
Prev. close $1.59 52-week low $0.85
Day low $1.53 Volume 193,136
Day high $1.61 Avg. volume 510,327
50-day MA $1.14 Dividend yield N/A
200-day MA $1.54 Market Cap 119.05M

Pieris Pharmaceuticals, Inc. (PIRS) Company Bio


Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin-based drugs. The company develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company is based in Boston, Massachusetts.


PIRS Latest News Stream


Event/Time News Detail
Loading, please wait...

PIRS Latest Social Stream


Loading social stream, please wait...

View Full PIRS Social Stream

Latest PIRS News From Around the Web

Below are the latest news stories about PIERIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PIRS as an investment opportunity.

While institutions own 32% of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), individual investors are its largest shareholders with 40% ownership

To get a sense of who is truly in control of Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ), it is important to...

Yahoo | January 17, 2023

Pieris to get $5M as Seagen starts dosing in phase 1 trial of cancer drug

Boston-based Pieris Pharmaceuticals (PIRS) said it achieved a $5M milestone from Seagen after the Bothell, Wash.-based company dosed the first patient in a phase 1 trial of cancer…

Seeking Alpha | January 10, 2023

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule

BOSTON, MA / ACCESSWIRE / January 10, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® te…

Finanz Nachrichten | January 10, 2023

Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)

/ Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other conditions, today announced that the Company has achieved a $5 million milestone from Seagen.

Yahoo | January 10, 2023

Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) Has Succeeded In Attracting Investors This Year, The Stock Is Down -75.93% Year-To-Date

Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)’s traded shares stood at 0.57 million during the last session, with the company’s beta value hitting 1.00. At the close of trading, the stock’s price was $0.91, to imply an increase of 3.41% or $0.03 in intraday trading. The PIRS share’s 52-week high remains $4.08, putting it -348.35% down since that … Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) Has Succeeded In Attracting Investors This Year, The Stock Is Down -75.93% Year-To-Date Read More »

Marketing Sentinel | December 24, 2022

Read More 'PIRS' Stories Here

PIRS Price Returns

1-mo 53.85%
3-mo 56.86%
6-mo -6.98%
1-year -56.04%
3-year -56.76%
5-year -79.14%
YTD 53.85%
2022 -72.49%
2021 51.20%
2020 -30.94%
2019 36.09%
2018 -64.77%

Continue Researching PIRS

Want to see what other sources are saying about Pieris Pharmaceuticals Inc's financials and stock price? Try the links below:

Pieris Pharmaceuticals Inc (PIRS) Stock Price | Nasdaq
Pieris Pharmaceuticals Inc (PIRS) Stock Quote, History and News - Yahoo Finance
Pieris Pharmaceuticals Inc (PIRS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.779 seconds.